3D Bioprinting Recognized as a Transformative Technology for Global Health
Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering pioneering 3D bioprinting technology, announced today that it has been recognized as a 2015 Technology Pioneer by the World Economic Forum (WEF). Organovo is one of 24 companies honored for the ability to harness creativity to design and create transformative solutions.
"We are honored to be named a Technology Pioneer by the World Economic Forum for the innovation and power of Organovo's 3D bioprinting technology," said Keith Murphy, president and CEO of Organovo. "We see this as a recognition of our team's hard work and dedication to our mission to improve health and medicine on a global scale."
Organovo's leading, commercial 3D bioprinting technology enables the creation of functional human tissues that more accurately reproduce native tissues. The company develops a range of tissue and disease models for medical research, drug testing and therapeutic applications.
"The impact of technology continues to accelerate in all domains of society," said Fulvia Montresor, director, head of Technology Pioneers at the World Economic Forum. "To better understand the breadth and depth of this impact, CEOs and other leaders have come to depend on their interactions with the Technology Pioneers and their diverse and innovative solutions."
Each year since 2000, the World Economic Forum chooses its Technology Pioneers from hundreds of applicants that are vetted by a distinguished selection committee of technology and innovation experts.
Organovo and the 2015 Technology Pioneers will be honored at a ceremony on September 11 at the eighth Annual Meeting of the New Champions. The Meeting is the foremost gathering in Asia on science, technology, innovation and entrepreneurship.
